SPRED2 and chronic myelogenous leukemia, BCR-ABL1 positive: SPRED2 can regulate the proliferation and apoptosis of chronic myelogenous leukemia and hepatoma cells and inhibit the growth of tumors by inhibiting the RAS/MAPK pathway25.